These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 32980347)
1. Evaluation of the treatment strategies on patient-derived xenograft mice of human breast tumor. Khalighfard S; Alizadeh AM; Poorkhani A; Motahari M; Tahmasebifar A; Omranipour R; Keshavarz P; Haddad P Eur J Pharmacol; 2020 Dec; 889():173605. PubMed ID: 32980347 [TBL] [Abstract][Full Text] [Related]
2. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857 [TBL] [Abstract][Full Text] [Related]
3. Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer. Turner TH; Alzubi MA; Sohal SS; Olex AL; Dozmorov MG; Harrell JC Breast Cancer Res Treat; 2018 Jul; 170(2):221-234. PubMed ID: 29532339 [TBL] [Abstract][Full Text] [Related]
4. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways. Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264 [TBL] [Abstract][Full Text] [Related]
5. Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers. Hatem R; Labiod D; Château-Joubert S; de Plater L; El Botty R; Vacher S; Bonin F; Servely JL; Dieras V; Bièche I; Marangoni E Int J Cancer; 2016 May; 138(10):2510-21. PubMed ID: 26686064 [TBL] [Abstract][Full Text] [Related]
6. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer. Garrett LA; Growdon WB; Rueda BR; Foster R J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models. Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216 [TBL] [Abstract][Full Text] [Related]
8. Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies. Eckhardt BL; Gagliardi M; Iles L; Evans K; Ivan C; Liu X; Liu CG; Souza G; Rao A; Meric-Bernstam F; Ueno NT; Bartholomeusz GA PLoS One; 2018; 13(5):e0195932. PubMed ID: 29768500 [TBL] [Abstract][Full Text] [Related]
9. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts. Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070 [TBL] [Abstract][Full Text] [Related]
10. [Arsenic trioxide restores ERα expression in ERα-negative human breast cancer cells and its treatment efficacy in combination with tamoxifen in xenografts in nude mice]. Zhang WJ; Xu DF; Fan QX; Wu XA; Wang F; Wang R; Wang LX Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):645-51. PubMed ID: 23159075 [TBL] [Abstract][Full Text] [Related]
11. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Raja SM; Clubb RJ; Ortega-Cava C; Williams SH; Bailey TA; Duan L; Zhao X; Reddi AL; Nyong AM; Natarajan A; Band V; Band H Cancer Biol Ther; 2011 Jan; 11(2):263-76. PubMed ID: 21088503 [TBL] [Abstract][Full Text] [Related]
12. Prognostic and functional importance of the engraftment-associated genes in the patient-derived xenograft models of triple-negative breast cancers. Moon HG; Oh K; Lee J; Lee M; Kim JY; Yoo TK; Seo MW; Park AK; Ryu HS; Jung EJ; Kim N; Jeong S; Han W; Lee DS; Noh DY Breast Cancer Res Treat; 2015 Nov; 154(1):13-22. PubMed ID: 26438141 [TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Buchsbaum DJ; Zhou T; Grizzle WE; Oliver PG; Hammond CJ; Zhang S; Carpenter M; LoBuglio AF Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3731-41. PubMed ID: 14506165 [TBL] [Abstract][Full Text] [Related]
14. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER Bihani T; Patel HK; Arlt H; Tao N; Jiang H; Brown JL; Purandare DM; Hattersley G; Garner F Clin Cancer Res; 2017 Aug; 23(16):4793-4804. PubMed ID: 28473534 [No Abstract] [Full Text] [Related]
15. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688 [TBL] [Abstract][Full Text] [Related]
16. Establishment and characterization of an ovarian yolk sac tumor patient-derived xenograft model. Luo M; He Y; Xie B; Li S; Gan F; Zhang S; Luo P Pediatr Surg Int; 2021 Aug; 37(8):1031-1040. PubMed ID: 34031745 [TBL] [Abstract][Full Text] [Related]
17. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer. Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535 [TBL] [Abstract][Full Text] [Related]
18. Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening. Fong EL; Martinez M; Yang J; Mikos AG; Navone NM; Harrington DA; Farach-Carson MC Mol Pharm; 2014 Jul; 11(7):2040-50. PubMed ID: 24779589 [TBL] [Abstract][Full Text] [Related]
19. Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems. Nagaria TS; Williams JL; Leduc C; Squire JA; Greer PA; Sangrar W Neoplasia; 2013 Aug; 15(8):939-51. PubMed ID: 23908594 [TBL] [Abstract][Full Text] [Related]
20. Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. Yu J; Qin B; Moyer AM; Sinnwell JP; Thompson KJ; Copland JA; Marlow LA; Miller JL; Yin P; Gao B; Minter-Dykhouse K; Tang X; McLaughlin SA; Moreno-Aspitia A; Schweitzer A; Lu Y; Hubbard J; Northfelt DW; Gray RJ; Hunt K; Conners AL; Suman VJ; Kalari KR; Ingle JN; Lou Z; Visscher DW; Weinshilboum R; Boughey JC; Goetz MP; Wang L Breast Cancer Res; 2017 Dec; 19(1):130. PubMed ID: 29212525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]